Farxiga significantly reduced hospitalisation for
12 November 2018 07:00 GMT Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial Fewer MACE events observed with Farxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier's gangrene with Farxiga vs. placebo AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-